摘要
目的评价小剂量奥美拉唑(0)联用瑞巴派特(R)对H.pylori相关性慢性浅表性胃炎的临床症状、内镜下黏膜变化及组织学炎症改善作用。方法采用随机平行对照临床研究。将96例H.pylori感染的慢性浅表性胃炎患者,随机分为OR组(32例)、0组(32例)、R组(32例)。治疗第1周,3组均予H.pylori根除三联方案。第2~6周,0组予洛赛克MUPS10mg每日1次13服;R组予膜固思达100mg每日3次口服;OR组予MUPS10mg每日1次口服,联合膜固思达100mg每日3次口服。结果治疗结束,3组临床症状改善均有显著性变化。OR组、0组临床症状改善均比R组显著。第6周末复查胃镜,镜下黏膜情况3组差异无统计学意义;OR组、R组组织学炎症消退均比0组明显。结论治疗H.pylori相关性慢性浅表性胃炎,小剂量奥美拉唑联合瑞巴派特,比两药单用能够更好缓解临床症状。促进炎症消退。
Objective To evaluate efficacy of clinical symptom relief, inflammation improvement by endoscopy, and the decresasing degree of inflammatory cells after the treatment of omeprazole combined with rebamipide (OR), omeprazole alone(O) or rebamipide(R) in patients of chronic superficial gastritis associated with H. pylori. Methods A randomized, parallel - controlled clinical study was conducted. Ninety - six patients with chronic superficial gastritis and H. pylori infection were randomized into the OR group( n = 32), the 0 .group(n = 32),and the R group(n = 32). In the first week, three groups received H. pylori three - drug eradication regimen. In the second to sixth week, the OR group was given omeprazole 10 rng once a day with rebamipide 100mg three times a day, the O group was given omeprazole 10 mg once a day, and the R group was given rebamipide 100mg three times a day. Results Among all three groups, the reductions of clinical symptoms, such as abdominal pain, abdominal distension, acid reflux and belching were significant. The OR and O group were more effective than the R group respectively. There was no significant difference among three groups in reducing severity of mucosa inflammation by endoscopy. Obvious inflammatory cells withdrawal was observed in the R and OR group at the end of six week. Conclusion In chronic superficial gastritis, the treatment of omeprazole combined with rebamipide may effectively relieve the dyspeptic symptoms and improve the mucosa inflammation as well than use anyone alone.
出处
《胃肠病学和肝病学杂志》
CAS
2006年第4期414-415,419,共3页
Chinese Journal of Gastroenterology and Hepatology